Slingshot members are tracking this event:

AbbVie files patent lawsuit seeking to stop Amgen’s copy of Humira

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ABBV Community voting in process
AMGN Community voting in process

Additional Information

Additional Relevant Details AbbVie is trying to protect a rheumatoid arthritis injection whose sales surged 17 percent in the second quarter to $4.15 billion. The drug accounted for 61 percent of AbbVie’s 2015 revenue. The litigation is only part of the hurdle for Amgen. The Thousand Oaks, California-based biotech company has to navigate a byzantine series of steps known as the “patent dance” that’s still being worked out by U.S. courts and regulators.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 05, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Humira, Patent Lawsuit